Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BPX-603 |
| Synonyms | |
| Therapy Description |
BPX-603 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) for ERBB2 (HER2) and a dual-switch consisting of chemical inducer of dimerization (CID)-inducible co-activation domain (MyD88/CD40) and an inducible caspase 9 safety switch (CaspaCIDe), which may lead to activation of anti-tumor immune responses in the tumor microenvironment (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BPX-603 | HER-2 Autologous GoCAR-T|BPX603|BPX 603 | HER2 (ERBB2) Immune Cell Therapy 9 | BPX-603 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) for ERBB2 (HER2) and a dual-switch consisting of chemical inducer of dimerization (CID)-inducible co-activation domain (MyD88/CD40) and an inducible caspase 9 safety switch (CaspaCIDe), which may lead to activation of anti-tumor immune responses in the tumor microenvironment (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|